Related Experiment Video
Updated: Feb 1, 2026
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
Rhabdomyosarcoma and Extraosseous Ewing Sarcoma
Juan P Gurria1, Roshni Dasgupta2
1Cincinnati Children's Hospital Medical Center, Division of Pediatric General and Thoracic Surgery, Cincinnati, OH 45229, USA. jpgurria@gmail.com.
Insights
This review details Rhabdomyosarcoma (RMS) and extraosseous Ewing sarcoma (EES), common pediatric soft tissue and bone cancers. It covers updated molecular diagnostics, risk stratification, and multidisciplinary treatment strategies for improved outcomes.
Area of Science:
- Pediatric Oncology
- Molecular Pathology
- Surgical Oncology
Background:
- Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma, originating from mesenchymal cells.
- Ewing sarcoma (ES) is a highly malignant bone tumor, with extraosseous Ewing sarcoma (EES) being a rare extraskeletal variant.
- Both RMS and ES are classified as small round blue cell tumors of childhood.
Purpose of the Study:
- To provide a comprehensive, evidence-based review of pediatric Rhabdomyosarcoma and extraosseous Ewing sarcoma.
- To update knowledge on molecular diagnostics, clinical presentation, and diagnostic approaches.
- To outline multidisciplinary management strategies based on the latest standards of care.
Main Methods:
- Review of current literature on pediatric RMS and EES.
- Analysis of molecular diagnostic tools and their impact on classification.
- Synthesis of evidence-based guidelines for multidisciplinary treatment.
Main Results:
- Recent advancements in molecular markers and diagnostic tools have refined RMS classification and risk stratification.
- Improved understanding of tumor biology aids in tailoring treatment approaches for pediatric RMS and EES.
- Multidisciplinary care is crucial for optimizing medical and surgical management.
Conclusions:
- Updated molecular and diagnostic strategies enhance the precision of pediatric RMS and EES classification and treatment.
- Evidence-based, multidisciplinary management is essential for improving patient outcomes.
- This review synthesizes current knowledge to guide the care of children with these rare tumors.
Abstract:
Rhabdomyosarcoma (RMS) is a malignant tumor that represents the most common form of pediatric soft tissue sarcoma. It arises from mesenchymal origin and forms part of the group of small round blue cell tumors of childhood. It has a constant annual incidence of 4.5 cases per 1,000,000 children. The known histological diagnosis of the two major subtypes (embryonal and alveolar) has been recently enhanced by tumor biological markers and molecular differentiation diagnostic tools that have improved not only the updated classification based on risk stratification, but also the treatment approach based on the clinical group. Ewing sarcoma (ES) is a round cell tumor, highly malignant and poorly differentiated that is currently the second most common malignant bone tumor in children. In rare instances, it develops from an extraskeletal origin, classified as extraosseous Ewing sarcoma (EES). We provide an updated, evidence-based and comprehensive review of the molecular diagnosis, clinical and diagnostic approach and a multidisciplinary medical and surgical management according to the latest standard of care for the treatment of pediatric RMS and EES.
